马雷辛1促进炎症的缓解,改善急性心力衰竭中左心室功能
Ganesh V Halade1,2, Kevin A Ingle3, Romain A Travis4
1Heart Institute, Division of Cardiovascular Sciences, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
British journal of pharmacology
|January 16, 2026
概括
高剂量的马雷辛1通过消除炎症和促进组织修复,改善心肌梗塞后的心脏功能. 这项研究强调了maresin 1作为心力衰竭的潜在治疗方法.
科学领域:
- 心血管研究研究心血管研究
- 炎症生物学 炎症生物学
- 再生医学是一种再生医学.
背景情况:
- 天生的炎症反应对于清除心肌梗塞 (MI) 后的碎片至关重要.
- 未解决的炎症会导致慢性炎症和心力衰竭.
- 专业的亲解决媒介 (SPMs),如maresin 1,由巨细胞产生,但它们在心脏修复中的治疗作用尚不清楚.
研究的目的:
- 为了研究外源性马瑞1在心肌梗塞 (MI) 后的心脏修复中的治疗潜力.
- 为了确定不同剂量的马雷辛1对心脏功能,炎症解消和心脏病后组织重塑的影响.
主要方法:
- 雄性C57BL/6J小鼠接受了冠状动脉绑定以诱导心脏病发作.
- 小鼠接受低剂量 (LD) 或高剂量 (HD) maresin 1次MI后皮下注射.
- 评估了心脏功能,白细胞动态,巨细胞表型和心炎症.
主要成果:
- 高剂量 (HD) maresin 1显著改善了心脏性能,并降低了心脏和肺部质量与体重的比率.
- HD-马林素1加速了中性粒细胞的清除,促进了修复性的巨细胞表型,并上调了FPR2受体表达.
- HD-马林素1减弱心炎症,以减少NGAL和脏内林表达增加为标志.
结论:
- 高剂量的马雷辛1激活FPR2信号,增强炎症解消,调节白细胞和巨细胞的动态.
- 马雷辛1治疗改善了心脏功能,并减轻了心脏发作后的心脏发炎.
- 马雷辛1在心脏愈合和治疗急性心力衰竭方面显示出显著的治疗潜力.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
01:14Myocarditis III: Medical Management
175
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
175
01:29Cardiomyopathy V: Interprofessional Care
339
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
339
01:20Mitral Regurgitation I: Introduction
423
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
423
01:25Mitral Regurgitation III: Medical Management
284
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
284